Skip to main content

CTOS 2023 Main banner

Schedule at a Glance

Icon Legend

This session is not in your schedule.

This session is in your schedule. Click again to remove it.

Back

Ingrid Mintautas, B.A

Associate Director, Clinical Operations
C4 Therapeutics

Poster(s):

(P 178) INITIAL RESULTS FROM A PHASE 1 STUDY OF CFT8634, A NOVEL BIFUCTIONAL DEGRADATION ACTIVATING COMPOUND (BIDAC) DEGRADER OF BRD9, IN SYNOVIAL SARCOMA AND SMARCB1-NULL TUMORS